Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies.

摘要: Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans experimental models. The overall objective present study was demonstrate that sphingomyelin (SM) cerebrospinal fluid (CSF) patients affected by demyelinating neuropathies is a biomarker. We found SM levels mirror peripheral myelination during development small rearrangements As acquired breakdown occurs, CSF these might detect loss. Indeed, quantification 262 neurological showed significant increase with demyelination (p = 3.81 * 10 − 8) compared subjects non-demyelinating disorders. Interestingly, alone able distinguish from axonal differs principal indexes, confirming novelty this potential index. In conclusion, specific sensitive biomarker monitor pathology neuropathies. Most importantly, assay simple, fast, inexpensive, promising be used clinical practice drug development.